top of page

Poster Presentations 

01 Emerging Concepts / New Agents


P01.01 Safety and Efficacy Study of Pembrolizumab in Combination With LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant as Neoadjuvant TherapY——PLENTY Randomized Clinical Trial
Presenting Author: Hao Feng, Shanghai, China

P01.02 TLR-mediated suppression of the CCL22-CCR4 axis as a new target for tumor immunotherapy
Presenting Author: Juliane Grün, München, Germany

P01.03 Targeting Diaclyglycerol Kinase alpha and zeta by self delivering RNAi to optimize Tlymphocytes for adoptive therapy of solid tumors
Presenting Author: Anna Herbstritt, Munich, Germany

P01.04 Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia
Presenting Author: Ramya Nair, Munich, Germany

P01.05 Deciphering the function of the ubiquitin-proteasome-system in regulating the immune checkpoint protein B7-H3 (CD276) in non-small cell lung cancer
Presenting Author: Marisa Kurz, Munich, Germany

P01.06 Overweight and obesity as biomarkers for survival outcomes and immune related adverse events undergoing immunotherapy - a systematic review and meta-analysis
Presenting Author: Paul Trinkner, Munich, Germany

P01.07 Depletion of CD206high tumour-associated macrophages using a nanoconjugate limits tumour burden & dissemination in metastatic triple negative breast cancer in mice
Presenting Author: Anni Lepland, Tartu, Estonia

P01.08 Sarcopenia as biomarker for immunotherapy outcomes and immune-related adverse events - a systematic review and meta-analysis
Presenting Author: Sophie Günther, München, Germany


02 Tumor microenvironment and microbiome in Immunotherapy


P02.01 T- and B-cell abundance are remarkably reduced in the immune microenvironment of post-transplant malignancies
Presenting Author: Simon Schran, Cologne, Germany

P02.02 Single-cell RNA sequencing of neuroblastoma tumors reveals immunoregulatory interactions as novel targets for immunotherapy
Presenting Author: Judith Wienke, Utrecht, Netherlands

P02.03 Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers.
Presenting Author: Niclas Blessin, Hamburg, Germany

P02.04 Tissue-Infiltrating Th9 cells in Human endometrial Cancer
Presenting Author: Huan TONG, Shanghai, China

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-small Cell Lung Cancer at Single Cell Resolution
Presenting Author: Yuan Cordts, Cologne, Germany

P02.06 Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence.
Presenting Author: Niclas Blessin, Hamburg, Germany

P02.07 Characterization of the tumor immune microenvironment of pediatric posterior fossa A ependymomas
Presenting Author: Julie Lammers, Utrecht, Netherlands

P02.08 The Role of FoxP3+ Regulatory T Cells and IDO+ Immune and Tumor Cells in Malignant Melanoma - an immunohistochemical study
Presenting Author: Satu Salmi, Kuopio, Finland

P02.09 Heteromerization of uPA and PAI-1 enforces pro-tumorigenic neutrophil trafficking to malignant tumors in breast cancer via VLDLr-dependent β2 integrin clustering
Presenting Author: Bernd Uhl, München, Germany

P02.10 FocuSCOPE: A single cell, multi-omics solution to simultaneously analyze tumor variants and microenvironment
Presenting Author: Yasaman Arjmand Abbassi, Köln, Germany

P02.11 TREM1 agonist PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity
Presenting Author: Vladi Juric, South San Francisco, United States

03 Vaccine Therapy

P03.01 High immunogenic VLP-based vaccines elicit new T cell specificities against melanoma neoantigens in mice
Presenting Author: Carmen Aguilar-Gurrieri, Badalona, Spain

P03.02 Protein-based cancer vaccine combined with an oncolytic vaccine promotes potent antitumor immunity
Presenting Author: Elodie Belnoue, Geneva, Switzerland

P03.03 Novel machine-learning tools improve cost-effective development of personalised immunotherapies: lowering false positive rates in the search for actionable immunogenic neoantigens
Presenting Author: Lore Van Oudenhove, Ghent, Belgium

P03.04 Novel algorithm discovers up to 35 percent more epitopes translated from non-coding regions in cold tumours
Presenting Author: Lore Van Oudenhove, Ghent, Belgium

P03.05 Evaluation of the neoepitope landscape and CD8+ T cell recognition of murine syngeneic tumor cell lines
Presenting Author: Sara Suarez Hernandez, Lyngby, Denmark

P03.06 Deciphering vaccine-induced neoepitope-specific T cell responses in a patient with H3K27M-mutant midline glioma WHO grade 4
Presenting Author: Katharina Lindner, Heidelberg, Germany

P03.07 Analysis of scRNAseq from the human thymus nominates genes potentially missing from central tolerance of cytotoxic T cells
Presenting Author: Lili Blumenberg, Tarrytown, United States

04 Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

P04.01 Immunomonitoring of CD19. CAR T-cells in Large B-Cell Lymphoma- a two-center experience
Presenting Author: Viktoria Blumenberg, Munich, Germany

P04.02 Diversity of CD4+ blood T-cell clonality predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma
Presenting Author: Akiko Arakawa, München, Germany

P04.03 Expression profiles of immune markers as predictors of survival in surgically-treated NSCLC
Presenting Author: Laura Sellmer, Munich, Germany

P04.04 Programmed death-ligand 1 positron emission tomography imaging during neoadjuvant (chemo)radiotherapy in esophageal and rectal cancer (PETNEC): a prospective non-randomized open-label single-center pilot study
Presenting Author: Johannes Laengle, Vienna, Austria

05 “Lost in Translation”?

P05.01 Organoid-specific optimization of killing assays to test novel immunotherapies in a high-throughput system
Presenting Author: Femke van den Ham, Utrecht, Netherlands

06 Cell Therapy in Solid Tumors

P06.01 αβ-T cells engineered to express γδ-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression
Presenting Author: Josephine Strijker, Utrecht, Netherlands

P06.02 Cancer-specific differences of tertiary lymphoid structures and cellular responses against frequently expressed cancer testis antigens
Presenting Author: Ella Preugszat, Cologne, Germany

P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models
Presenting Author: Mohamed-Reda Benmebarek, Munich, Germany

P06.04 Transcriptome-wide network analysis predicts the role of lactate dehydrogenase C in breast cancer cell survival and immune dysfunction
Presenting Author: Adviti Naik, Doha, Qatar

P06.05 Endogenous T-cell responses to ten major cancer testis antigens are frequent in esophago-gastric adenocarcinoma and antigen-specific T cells can be expanded using CD40-activated B cells
Presenting Author: Martin Thelen, Cologne, Germany

P06.06 Enhancing trafficking and resistance to immunosuppression of synthetic agonistic receptor-transduced T cells in solid tumor models
Presenting Author: Melanie Schwerdtfeger, Munich, Germany

P06.07 In vivo studies of immunomodulatory a-CTLA-4 antibody in a humanized mouse model
Presenting Author: Carmen Reitinger, Erlangen, Germany

07 Cell Therapy in Haematologic Diseases

P07.01 A modular and controllable T cell therapy platform for AML
Presenting Author: Mohamed-Reda Benmebarek, Munich, Germany

P07.02 Regulation of CD19 CAR T- cell activation based on engineered Nuclear factor of activated T cells artificial transcription factors
Presenting Author: Duško Lainšček, Ljubljana, Slovenia

P07.03 “myTcell”: A smartphone applicationguides logisticsand management of CAR T-cell & BiTE related toxicities
Presenting Author: Viktoria Blumenberg, Munich, Germany

08 Combination Therapy

P08.01 Rationale of using the combination of anti-PD-1 antibody and anti-IL-8 antibody for the pancreatic cancer treatment
Presenting Author: Jessica Gai, Baltimore, United States

P08.02 CCR2/CCR5 dual-antagonist “licenses” the radiation-induced effector T-cell infiltration in the anti-PD-1 antibody-treated pancreatic adenocarcinoma
Presenting Author: Jianxin Wang, Hangzhou, China

P08.03 Neoantigen cancer vaccine auguments anti CTLA-4 efficacy
Presenting Author: Fabio Palombo, Rome, Italy

P08.04 Successful immunotherapy of the breast cancer metastatic disease in mice using a pharmaceutical TLR4-agonist induces systemic anti-tumor T cell response and long-term T cell memory
Presenting Author: Ekaterina Ushakova, Moscow, Russian Federation

P08.05 Combined pharmacological targeting of adenosine 2a- and 2b-receptor enhances CAR T cell function
Presenting Author: Matthias Seifert, Munich, Germany

P08.06 Combining RIG-I-targeted immune activation with CAR T cell therapy induces efficient tumor control in murine pancreatic cancer models
Presenting Author: Anne Senz, München, Germany

09 Young Researcher Session

P09.01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell cytotoxicity.

Presenting Author: Gabrielle Leclercq, Schlieren, Switzerland

P09.02 Epigenetic modulation of neuroblastoma enhances T- and NK cell immunogenicity via induction of surface expression of MHC class I and MICA/MICB
Presenting Author: Annelisa Cornel, Utrecht, Netherlands

P09.03 Hyaluronic acid as a new immunologic adjuvant in cancer: design of effective preventive and therapeutic vaccination strategies for HER2/neu-positive breast tumors
Presenting Author: Debora Carpanese, Padova, Italy

P09.04 Impact of major oncologic surgery on immune responses in the immediate post-operative setting in oesophageal adenocarcinoma patients; a guide to harnessing the double-edged sword of cancer surgery
Presenting Author: Noel Donlon, Dublin, Ireland

P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer
Presenting Author: Ikuan Sam, Paris, France

P09.06 Investigating various patient parameters as prognostic markers for patients with advance stage nasopharyngeal carcinoma undergoing induction chemotherapy followed by Epstein-Barr virus cytotoxic T-lymphocyte immunotherapy
Presenting Author: Axel Jun Ming Chu, Singapore, Singapore

P09.07 Novel insights into immune-independent functions of immune checkpoint inhibitors in oesophageal adenocarcinoma; potential implications for designing combination immuno-chemotherapy regimens to achieve synergistic responses
Presenting Author: Maria Davern, Dublin, Ireland 


bottom of page